{"id":60503,"date":"2025-01-23T22:27:01","date_gmt":"2025-01-23T22:27:01","guid":{"rendered":"https:\/?p=60503"},"modified":"2025-01-23T22:27:01","modified_gmt":"2025-01-23T22:27:01","slug":"abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/","title":{"rendered":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4"},"content":{"rendered":"<div class=\"flex-1 overflow-hidden @container\/thread\">\n<div class=\"h-full\">\n<div class=\"react-scroll-to-bottom--css-wtuqe-79elbk h-full\">\n<div class=\"react-scroll-to-bottom--css-wtuqe-1n7m0yu\">\n<div class=\"flex flex-col text-sm md:pb-9\">\n<article class=\"w-full scroll-mb-[var(--thread-trailing-height,150px)] text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-97\" data-scroll-anchor=\"true\">\n<div class=\"m-auto text-base py-[18px] px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\">\n<div class=\"mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\">\n<div class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn\">\n<div class=\"flex-col gap-1 md:gap-3\">\n<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"e98f4bd3-dcb3-4b0d-b582-24022a2d6e5a\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<h2>Abbott Laboratories (ABT)<\/h2>\n<p>Evercore ISI&#8217;s <a href=\"https:\/\/www.stocktargetadvisor.com\/Analyst-Ranking\/Evercore-ISI\">(Analyst Rank#37)<\/a> decision to <strong>raise the target price of Abbott Laboratories (NYSE: ABT) to $138 from $136<\/strong> reflects optimism about the company\u2019s future performance, primarily driven by its strong fourth-quarter earnings and favorable fiscal year 2025 guidance.<\/p>\n<p><strong>Let\u2019s break this down in detail:<\/strong><\/p>\n<hr \/>\n<h3><strong>1. Solid Fourth-Quarter Earnings<\/strong><\/h3>\n<ul>\n<li><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/ABT\/analyst-rating\">Abbott\u2019s<\/a> robust Q4 earnings indicate the company\u2019s ability to deliver strong financial results despite broader macroeconomic pressures, such as rising costs and slower global growth.<\/li>\n<li>Key drivers of the strong earnings may include:\n<ul>\n<li><strong>Steady performance across its core segments,<\/strong> such as medical devices, diagnostics, nutrition, and established pharmaceuticals.<\/li>\n<li><strong>Strong demand for innovative products,<\/strong> particularly in its diabetes care segment (e.g., FreeStyle Libre continuous glucose monitors), which has been a major growth driver.<\/li>\n<li>Continued recovery in non-COVID-related healthcare services and elective procedures, supporting revenue growth in its medical devices segment.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<hr \/>\n<h3><strong>2. FY25 Guidance<\/strong><\/h3>\n<ul>\n<li>Abbott\u2019s fiscal year 2025 guidance appears to reflect confidence in sustained revenue growth and margin expansion. This likely stems from:\n<ul>\n<li><strong>Pipeline of new product launches<\/strong>: Abbott&#8217;s investments in R&amp;D continue to yield cutting-edge solutions, particularly in high-demand areas like diabetes management, cardiovascular care, and diagnostics.<\/li>\n<li><strong>Resilient global demand<\/strong> for healthcare solutions, even in a potentially slower economic environment.<\/li>\n<li><strong>Focus on operational efficiency,<\/strong> with strong operational leverage allowing the company to expand margins and drive bottom-line growth.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Evercore ISI likely views this guidance as an indicator of Abbott\u2019s ability to navigate challenges while maintaining strong financial performance.<\/p>\n<hr \/>\n<h3><strong>3. Underlying Strength on the Top Line<\/strong><\/h3>\n<ul>\n<li>Abbott\u2019s revenue growth is expected to benefit from:\n<ul>\n<li><strong>Increased adoption of medical technologies<\/strong>, especially in emerging markets, where access to healthcare is rapidly expanding.<\/li>\n<li><strong>Growing demand for diagnostics products<\/strong>, driven by a global focus on preventive care and chronic disease management.<\/li>\n<li><strong>Momentum in the nutrition business,<\/strong> with brands like Ensure and Pedialyte continuing to perform well across global markets.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>These trends suggest Abbott is positioned for sustained growth across its key business segments.<\/p>\n<hr \/>\n<h3><strong>4. Strong Operational Leverage<\/strong><\/h3>\n<ul>\n<li>Operational leverage refers to the ability of a company to grow profits faster than revenues by maintaining a cost-efficient structure. Abbott\u2019s strong operational leverage is likely supported by:\n<ul>\n<li><strong>Efficiencies in manufacturing and supply chains,<\/strong> despite inflationary pressures.<\/li>\n<li><strong>Scalable product offerings,<\/strong> particularly in diagnostics and medical devices, which have high gross margins.<\/li>\n<li>Disciplined cost control measures, ensuring that incremental revenues translate effectively into higher profits.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>This operational discipline enhances investor confidence in the company\u2019s ability to deliver consistent earnings growth.<\/p>\n<hr \/>\n<h3><strong>Investor Implications<\/strong><\/h3>\n<ol>\n<li><strong>For Growth-Oriented Investors:<\/strong>\n<ul>\n<li>Abbott&#8217;s strong Q4 earnings and promising FY25 guidance suggest a reliable growth trajectory, making it an attractive option for long-term investors focused on healthcare innovation.<\/li>\n<\/ul>\n<\/li>\n<li><strong>For Value-Oriented Investors:<\/strong>\n<ul>\n<li>Although the target price increase is modest, Abbott\u2019s consistent operational performance and dividend history (part of the Dividend Aristocrats) could make it appealing as a stable, income-generating stock.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Overall Sentiment:<\/strong>\n<ul>\n<li>Evercore ISI\u2019s revised target reflects a <strong>balanced optimism<\/strong>: While acknowledging Abbott\u2019s underlying strengths and growth potential, the modest adjustment signals awareness of broader market conditions or potential sector-specific challenges.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<hr \/>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full\">\n<div>\n<div class=\"relative w-full px-2 py-2 text-center text-xs text-token-text-secondary empty:hidden md:px-[60px]\">\n<div class=\"min-h-4\">\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abbott Laboratories (ABT) Evercore ISI&#8217;s (Analyst Rank#37) decision to raise the target price of Abbott Laboratories (NYSE: ABT) to $138 from $136 reflects optimism about&#8230;<\/p>\n","protected":false},"author":3,"featured_media":3137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60503","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4\" \/>\n<meta property=\"og:description\" content=\"Abbott Laboratories (ABT) Evercore ISI&#8217;s (Analyst Rank#37) decision to raise the target price of Abbott Laboratories (NYSE: ABT) to $138 from $136 reflects optimism about...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-23T22:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2020\/11\/abbot-labs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4\",\"datePublished\":\"2025-01-23T22:27:01+00:00\",\"dateModified\":\"2025-01-23T22:27:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\"},\"wordCount\":511,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\",\"name\":\"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-01-23T22:27:01+00:00\",\"dateModified\":\"2025-01-23T22:27:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/","og_locale":"en_US","og_type":"article","og_title":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4","og_description":"Abbott Laboratories (ABT) Evercore ISI&#8217;s (Analyst Rank#37) decision to raise the target price of Abbott Laboratories (NYSE: ABT) to $138 from $136 reflects optimism about...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-01-23T22:27:01+00:00","og_image":[{"width":1600,"height":900,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2020\/11\/abbot-labs.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4","datePublished":"2025-01-23T22:27:01+00:00","dateModified":"2025-01-23T22:27:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/"},"wordCount":511,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/","name":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-01-23T22:27:01+00:00","dateModified":"2025-01-23T22:27:01+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbott-laboratories-evercore-isi-raises-valuation-on-strong-q4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Abbott Laboratories: Evercore ISI Raises Valuation on Strong Q4"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/60503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=60503"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/60503\/revisions"}],"predecessor-version":[{"id":60507,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/60503\/revisions\/60507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/3137"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=60503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=60503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=60503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}